Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing
Merck To Acquire Bio-Techne For $73 Per Share In Cash At EV Of $11.3B; Deal Expected To Be Immediately Accretive To Sales Growth And EBITDA Pre Margin And EPS Pre Accretive By Year 3 Post-Closing
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day